All In Biotech

Drug Trial Radar · NCT06590740

Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.

Establishment of a FeNO Cutoff Value for Evaluating the Response to Budesonide-formoterol in Patients With Chronic Cough Suggestive of Cough Variant Asthma: a Multicenter Prospective Clinical Study

Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,000

Actual

Start

Oct 18, 2024

Primary completion

Sep 3, 2025

Study completion Sep 3, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, prospective, single-arm, interventional clinical study to predict the response to budesonide-formoterol treatment in patients with chronic dry or nocturnal cough by determining a cut off value of FeNO. In this study, the response to ICS/LABA treatment is defined as reduction in cough VAS score from baseline of ≥30 mm after 8 weeks of ICS/LABA treatment. Subjects will be treated with Symbicort® 160/4.5 mcg, 1 puff, BID for 8 weeks with 4 study visits: Visit 1 (Day 0), Visit 2 (week 4) and Visit 3, end of study (week 8) and Visit 4, 4 weeks after treatment discontinuation, (week 12). Baseline data will be collected at Day-5 to Day0. This study will be conducted at around 40 study sites in China. Approximately 1000 patients (age ≥18 years old) with dry cough or nocturnal cough symptoms for at least 8 weeks and no other obvious cause for their cough will be enrolled into this study.

Conditions

  • Cough-Variant Asthma

Interventions

  • Budesonide-Formoterol treatmentDrug

    Budesonide 160 μg/formoterol 4.5 μg, 1 inhalation, BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To obtain a cut-off value for FeNO which can be used to distinguish responsiveness to 8 weeks treatment of Budesonideformoterol (based on visual analog scale [VAS]).Time frame: 8 weeks

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Benxi, China

  • Research Site

    Chengdu, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Dongguan, China

  • Research Site

    Fenyang, China

  • Research Site

    Fuzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guiyang, China

  • Research Site

    Heifei, China

  • Research Site

    Heze, China

  • Research Site

    Huizhou, China

  • Research Site

    Jiaxing, China

  • Research Site

    Jinhua, China

  • Research Site

    Liuzhou, China

  • Research Site

    Nanchang, China

  • Research Site

    Nanjing, China

  • Research Site

    Nanyang, China

  • Research Site

    Quanzhou, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shangqiu, China

  • Research Site

    Shenzhen, China

  • Research Site

    Shijiazhuang, China

  • Research Site

    Suzhou, China

  • Research Site

    Taiyuan, China

  • Research Site

    Taiyuan, China

  • Research Site

    Weifang, China

  • Research Site

    Wenzhou, China

  • Research Site

    Wenzhou, China

  • Research Site

    Xi'an, China

  • Research Site

    Xiangtan, China

  • Research Site

    Yantai, China

  • Research Site

    Zhengzhou, China

  • Research Site

    Zunyi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.